| 0 (0%) | 10-14 18:22 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.76 | 1-year : | 2.06 |
| Resists | First : | 1.51 | Second : | 1.76 |
| Pivot price | 1.38  |
|||
| Supports | First : | 1.09 | Second : | 0.9 |
| MAs | MA(5) : | 1.36 |
MA(20) : | 1.36  |
| MA(100) : | 1.06 |
MA(250) : | 1.5 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 22.4 |
D(3) : | 34.2 |
| RSI | RSI(14): 46.7 |
|||
| 52-week | High : | 2.81 | Low : | 0.71 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ IFRX ] has closed above bottom band by 21.3%. Bollinger Bands are 36.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.3 - 1.3 | 1.3 - 1.31 |
| Low: | 1.11 - 1.12 | 1.12 - 1.13 |
| Close: | 1.27 - 1.28 | 1.28 - 1.29 |
Tue, 14 Oct 2025
Should I hold or sell IFRX stock in 2025 - Global Markets & Weekly Stock Breakout Alerts - newser.com
Tue, 14 Oct 2025
Using flow based indicators on IFRX - Portfolio Update Summary & Low Drawdown Trading Strategies - newser.com
Tue, 14 Oct 2025
Forecasting IFRX price range with options data - Portfolio Performance Summary & AI Based Buy/Sell Signal Reports - newser.com
Tue, 07 Oct 2025
Leerink Partners Maintains InflaRx(IFRX.US) With Buy Rating, Maintains Target Price $2 - 富途牛牛
Fri, 03 Oct 2025
InflaRx N.V. (NASDAQ:IFRX) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Thu, 21 Aug 2025
Biotech Innovator InflaRx to Showcase Anti-Inflammatory Pipeline at Major September Healthcare Conferences - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 0 (M) |
| Shares Float | 68 (M) |
| Held by Insiders | 5.694e+007 (%) |
| Held by Institutions | 6.3 (%) |
| Shares Short | 453 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -5.248e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -35 % |
| Return on Assets (ttm) | 91.1 % |
| Return on Equity (ttm) | -39.5 % |
| Qtrly Rev. Growth | 162830 % |
| Gross Profit (p.s.) | 369 |
| Sales Per Share | -46.15 |
| EBITDA (p.s.) | -3.53901e+006 |
| Qtrly Earnings Growth | -0.9 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -43 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.03 |
| Price to Cash Flow | 2.14 |
| Dividend | 0 |
| Forward Dividend | 718430 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|